|
Release Date: November 13, 2009
Expiration Date: November 13, 2010
Estimated time to complete activity: 1 hour
Faculty
Sally L. Hodder, MD
Professor of Medicine
New Jersey Medical School
University of Medicine & Dentistry of New Jersey
Newark, NJ
Paul E. Sax, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director
Division of Infectious Diseases and HIV Program
Brigham and Women’s Hospital
Boston, MA
Activity Overview
This activity will provide participants with important up-to-date information regarding the latest findings in HIV epidemiology, comorbidities, HIV therapies for treatment-naïve and -experienced patients, and strategies for managing virologic failure and ART-related adverse effects.
Target Audience
This activity is designed for health care practitioners (physicians, physician assistants, nurse practitioners, registered nurses) involved in the management of HIV patients.
Educational Objectives
-Identify recent developments in the field of HIV research, including epidemiology, transmission, access to care, and updates to treatment guidelines
-Analyze the latest data from clinical trials regarding the use of existing and novel antiretroviral agents for the treatment of naïve and experienced patients with HIV, including strategies to overcome drug resistance
-Develop and implement strategies with which to integrate the latest treatment data, as well as new information
regarding drug toxicities and comorbidities into the whole health care of patients with HIV
Accrediation Statements
Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Kentucky
College of Medicine and HealthmattersCME. The University of Kentucky College of Medicine is accredited by the
ACCME to provide continuing medical education for physicians. The University of Kentucky College of Medicine
designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are
expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the
publication is provided solely by faculty who have been selected because of recognized expertise in their field.
All faculty members participating in continuing medical education programs sponsored by the University of Kentucky College of Medicine are expected to disclose any real or perceived conflict of interest related to the content of the
publications. Faculty disclosures are listed below.
Nursing
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of
program content nor commercial sponsors. This educational activity is offered for a maximum of 1.0 ANCC and 1.2 KBN contact hours for nurses who complete the entire program. Provider #: 3-0008-01-13-202. In order to receive credit,
participants complete CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the program is completed.
The University of Kentucky is an Equal Opportunity University.
Financial Disclosures
Sally L. Hodder, MD
Speakers Bureau: Bristol-Myers Squibb
Contract Research Support: Bristol-Myers Squibb, Gilead Sciences, Pfizer Inc, Tibotec
Consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Tibotec
Spouse’s Financial Interest: Retired Merck employee
Paul E. Sax, MD
Consultant: Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Tibotec
Teaching Honoraria: Abbott, Bristol-Myers Squibb, Gilead Sciences, Merck, Tibotec
*This issue of POSITIVE PULSE is an independent CME/CE-certified activity commenting on findings from ICAAC 2009 and is not an official publication of the conference.

This activity is jointly sponsored by the University of Kentucky Colleges of Medicine and Nursing and
HealthmattersCME.
This activity is supported by independent educational grants from Gilead Sciences Medical Affairs and
Bristol-Myers Squibb.
**Once the "Launch Activity" button is clicked, it may take a minute or more to download.
|